[ad_1]
A Missouri House committee has unanimously approved a bill to legalize the medical use of psilocybin by military veterans and fund studies exploring the therapeutic potential of the psychedelic.
The House Veterans Committee passed the legislation from Rep. Aaron McMullen (R) on Tuesday, with amendments to align it with a Senate companion version that moved through a panel in that chamber last week.
The revised bill text of the House measure—which received an initial committee hearing last month—hasn’t been published yet, but the Senate version as recently amended would allow military veterans who are at least 21 and are diagnosed with a qualifying condition such as post-traumatic stress disorder (PTSD) or substance use disorders to legally access laboratory-tested psilocybin.
In order to receive legal protections under the legislation, participants would need to be enrolled, or have sought enrollment, in a study involving the psychedelic.
There are also numerous requirements for patients to provide the state Department of Mental Health (DMH) with information about their diagnosis, the person who would be administering psilocybin and other details on the place and time of the treatment sessions.
Psilocybin could only be administered over a maximum of a one-year period, with the amount of the psychedelic used in that treatment capped at 150 milligrams, though qualifying patients could be also approved to continue for subsequent one-year periods.
Regulators, physicians and state agency officials would all be protected from legal consequences related to activity made lawful under the legislation.
Also, the legislation calls for DMH to provide funding to support research into the therapeutic potential of psilocybin.
The measure further expands the state’s Right to Try statute to allow people with life-threatening or severely debilitating conditions to access experimental controlled substances, in addition to those with terminal illnesses as is the case under current law. It would strike language that prohibits the use of Schedule I drugs, an initial step to potentially opening up access to other substances such as additional psychedelics.
Additionally, it states that psilocybin research can be done by “an institution of higher education in this state or contract research organizations conducting trials approved by the United States Food and Drug Administration.”
The legislation takes its lead from a separate House bill that advanced to the floor of that chamber last year but was not ultimately enacted.
A growing number of states are pursuing psychedelics reform legislation this session, with a focus on research and therapeutic access.
—
Marijuana Moment is tracking more than 1,000 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
For example, a Vermont legislative panel continued its consideration last week of a bill that would legalize psilocybin in the state and establish a work group on how to further regulate psychedelics for therapeutic use.
Also last week, the Arizona Senate passed a bipartisan bill that would legalize psilocybin service centers where people could receive the psychedelic in a medically supervised setting.
The governor of New Mexico recently endorsed a newly enacted resolution requesting that state officials research the therapeutic potential of psilocybin and explore the creation of a regulatory framework to provide access to the psychedelic.
The Connecticut legislature’s joint Judiciary Committee filed a bill to decriminalize psilocybin.
An Illinois senator recently introduced a bill to legalize psilocybin and allow regulated access at service centers in the state where adults could use the psychedelic in a supervised setting—with plans to expand the program to include mescaline, ibogaine and DMT.
Alaska House and Senate committees are considering legislation that would create a task force to study how to license and regulate psychedelic-assisted therapy in anticipation of eventual federal legalization of substances like MDMA and psilocybin.
Lawmakers in Hawaii are also continuing to advance a bill that would provide some legal protections to patients engaging in psilocybin-assisted therapy with a medical professional’s approval.
New York lawmakers also said that a bill to legalize psilocybin-assisted therapy in that state has a “real chance” of passing this year.
An Indiana House committee, meanwhile, approved a Republican-led bill last week that would fund clinical research trials into psilocybin that has already cleared the full Senate.
Bipartisan California lawmakers also recently introduced a bill to legalize psychedelic service centers where adults 21 and older could access psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators.
A Nevada joint legislative committee held a hearing with expert and public testimony on the therapeutic potential of substances like psilocybin in January. Law enforcement representatives also shared their concerns around legalization—but there was notable acknowledgement that some reforms should be enacted, including possible rescheduling.
The governor of Massachusetts recently promoted the testimony of activists who spoke in favor of her veterans-focused bill that would, in part, create a psychedelics work group to study the therapeutic potential of substances such as psilocybin.
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
[ad_2]
Source link
